Literature DB >> 31119314

Glucagon-like peptide-1 receptor agonists and fracture risk-limitations to current knowledge.

K Hygum1, T Harsløf1, B Langdahl1, J Starup-Linde2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31119314     DOI： 10.1007/s00198-019-05013-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  5 in total

1.  Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.

Authors:  Y S Zhang; W Y Weng; B C Xie; Y Meng; Y H Hao; Y M Liang; Z K Zhou
Journal:  Osteoporos Int       Date:  2018-08-06       Impact factor: 4.507

2.  Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.

Authors:  Guillaume Mabilleau; Aleksandra Mieczkowska; Daniel Chappard
Journal:  J Diabetes       Date:  2013-11-22       Impact factor: 4.006

Review 3.  Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.

Authors:  Bin Su; Hui Sheng; Manna Zhang; Le Bu; Peng Yang; Liang Li; Fei Li; Chunjun Sheng; Yuqi Han; Shen Qu; Jiying Wang
Journal:  Endocrine       Date:  2014-07-30       Impact factor: 3.633

4.  The use of incretins and fractures - a meta-analysis on population-based real life data.

Authors:  Johanna H M Driessen; Frank de Vries; Hein van Onzenoort; Nicholas C Harvey; Cees Neef; Joop P W van den Bergh; Peter Vestergaard; Ronald M A Henry
Journal:  Br J Clin Pharmacol       Date:  2016-12-07       Impact factor: 4.335

5.  Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.

Authors:  Johanna H M Driessen; Hein A W van Onzenoort; Jakob Starup-Linde; Ronald Henry; Andrea M Burden; Cees Neef; Joop P van den Bergh; Peter Vestergaard; Frank de Vries
Journal:  Calcif Tissue Int       Date:  2015-07-17       Impact factor: 4.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.